Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
about
Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trialsAncillary approaches to plasminogen activators.Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysisInterspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugsEndovascular management of acute ischemic stroke: advances in patient and treatment selection.Pharmacologic reperfusion therapy with indigenous tenecteplase in 15,222 patients with ST elevation myocardial infarction - the Indian RegistryTreatment of acute ischemic stroke: intravenous and endovascular therapies.How to make better use of thrombolytic therapy in acute ischemic stroke.Pharmacological revascularization of acute ischaemic stroke: focus on challenges and novel strategies.Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications.Clinical trials in acute ischemic stroke.Should minor stroke patients be thrombolyzed? A focused review and future directions.Use of Intra-arterial Thrombolytic Therapy for Acute Treatment of Frostbite in 62 Patients with Review of Thrombolytic Therapy in Frostbite.Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke.Current and future perspectives on the treatment of cerebral ischemia.Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries.Comparison of clot lysis activity and biochemical properties of originator tenecteplase (Metalyse(®)) with those of an alleged biosimilarEdaravone (Radicut), a free radical scavenger, is a potentially useful addition to thrombolytic therapy in patients with acute ischemic stroke.Systemic thrombolysis with the use of tenecteplase for segmental acute renal in-farction potentially associated with multiple thrombophilic gene polymorphismsRationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes.Thrombolysis for Massive Pulmonary Embolism in Pregnancy.Tenecteplase compared with streptokinase and heparin in the treatment of pulmonary embolism: an observational study.Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins
P2860
Q28079662-EA03808C-2FC1-4D47-A6C9-1A7DD6DD4319Q31095961-5EFB8D19-ED79-48A9-A745-E6BA54A6DFB6Q33714889-07AE4411-F52E-4DF1-B25C-3D3F594F96B2Q34011214-7972C494-F157-4741-BD8D-01B5CF5E9E33Q36730655-DA98AD7B-155C-4145-AA42-33C562C4BAAAQ37386869-5FC98541-3817-4092-9544-307242D60969Q37451515-C08EF4BF-8348-4C38-843E-EA2BD129C604Q37889116-791C57FE-E319-476A-AA6B-80B61672773FQ37997491-5F521B41-5F88-41E6-B129-350F590C3C5CQ38225341-4E3A07A0-AA95-4C77-A828-BEFB50045B8FQ38243696-4B0CB51E-BB14-4F42-8E7E-A84F52ECE8A9Q38302755-3D5FFF03-71F3-47AF-8007-A58D1530261FQ38464051-504E4A12-B44A-48A5-8B36-1606599BCF36Q38589822-0868E849-A73F-4E8C-9FE4-CB77A4247AB2Q38732640-B44BB2B0-BC77-495C-92CE-D58F14BA7AECQ38917550-4B6B35EC-BFA8-43B8-A965-74AB82D7AC74Q39394485-0CC7132D-9A00-4D93-87A5-E79FEE5AA4ADQ41914956-63DF6149-ECF5-405F-9518-8A19569E19CDQ42408578-18C063E0-F63E-453B-B5E9-18FDDDDB6602Q42739318-70E61CD0-DB9D-4198-9B5C-FC6912A6F986Q43696881-6E929397-5E41-4BCA-9189-051ECDD694DFQ48005364-9F2E7F86-723C-4EE8-845E-D169B8EBF68BQ49376842-B4AD9070-A9FE-4527-BF13-CFE0E8EEFFC7Q58869607-9C635497-E9AF-48CF-A243-8D5B2B62750D
P2860
Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacokinetics and pharmacod ...... f acute myocardial infarction.
@ast
Pharmacokinetics and pharmacod ...... f acute myocardial infarction.
@en
type
label
Pharmacokinetics and pharmacod ...... f acute myocardial infarction.
@ast
Pharmacokinetics and pharmacod ...... f acute myocardial infarction.
@en
prefLabel
Pharmacokinetics and pharmacod ...... f acute myocardial infarction.
@ast
Pharmacokinetics and pharmacod ...... f acute myocardial infarction.
@en
P2093
P1476
Pharmacokinetics and pharmacod ...... of acute myocardial infarction
@en
P2093
Paul Tanswell
Thierry Danays
P304
P356
10.2165/00003088-200241150-00001
P577
2002-01-01T00:00:00Z
P6179
1002364730